Immuno-Oncology | Specialty

Nivolumab Continues to Improve Outcomes in Advanced Melanoma

January 6th 2016

Victoria Atkinson, MD, discusses the impact of the phase III CheckMate-066 trial and nivolumab’s future as both a monotherapy and in combination with other therapies.

Expert Discusses Promising Pembrolizumab Triplet in Advanced Myeloma

January 5th 2016

Jesus San Miguel, MD, PhD, discusses a phase I study examining pembrolizumab added to lenalidomide and low-dose dexamethasone in patients with heavily pretreated relapsed/refractory multiple myeloma, while emphasizing the need for further follow-up.

Dr. Luke on the Future of Combination Therapy in Melanoma

January 5th 2016

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

Leading Checkpoint Researcher Optimistic About New Targets

December 29th 2015

Thomas F. Gajewski, MD, PhD, discusses how the field of immune checkpoints is expanding beyond PD-1 and CTLA-4.

PD-1 Success Fuels Interest in Many Immune System Targets

December 28th 2015

It is becoming increasingly clear that PD-1/ PD-L1 and CTLA-4 represent just the tip of the iceberg when it comes to manipulating the immune system to fight cancer, and the number of known checkpoints—and with it the list of potential drug targets—has expanded in recent years.

Importance of BRAF Testing Grows as Options Expand in Melanoma

December 28th 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

Pembrolizumab Indication Expanded, EC Approves T-VEC, and More

December 26th 2015

Pembrolizumab Improves Survival in PD-L1-Positive NSCLC

December 20th 2015

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

Lenvatinib in Metastatic Renal Cell Carcinoma

December 19th 2015

PD-1 Inhibition in Metastatic Renal Cell Carcinoma

December 19th 2015

Perspectives on Sequencing in Metastatic RCC

December 19th 2015

Goals in Relapsed/Refractory Metastatic RCC

December 19th 2015

mTOR Inhibition for Poor-Risk RCC

December 19th 2015

Frontline Therapy Selection in Metastatic RCC

December 19th 2015

Frontline TKI Selection in Metastatic RCC

December 19th 2015

First-Line Considerations in Metastatic Renal Cell Carcinoma

December 19th 2015

T-VEC Approved in Europe for Unresectable Metastatic Melanoma

December 18th 2015

The European Commission has approved talimogene laherparepvec as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera.

FDA Approves Two New Indications for Pembrolizumab in Advanced Melanoma

December 18th 2015

The FDA has expanded the approval for single-agent pembrolizumab to include the frontline treatment of patients with advanced melanoma regardless of BRAF status.

Urologists Adapt Treatment Paradigm to Incorporate Novel Agents in mCRPC

December 15th 2015

Raoul S. Concepcion, MD, FACS, discussed novel therapies for treating mCRPC and deciding which patients are appropriate candidates.

Dr. Petrylak on Atezolizumab in Bladder Cancer

December 15th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.